PL2291368T3 - Podstawione gama laktamy jako środki terapeutyczne - Google Patents
Podstawione gama laktamy jako środki terapeutyczneInfo
- Publication number
- PL2291368T3 PL2291368T3 PL09734653T PL09734653T PL2291368T3 PL 2291368 T3 PL2291368 T3 PL 2291368T3 PL 09734653 T PL09734653 T PL 09734653T PL 09734653 T PL09734653 T PL 09734653T PL 2291368 T3 PL2291368 T3 PL 2291368T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic agents
- substituted gamma
- gamma lactams
- lactams
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4750108P | 2008-04-24 | 2008-04-24 | |
| PCT/US2009/041389 WO2009132088A1 (en) | 2008-04-24 | 2009-04-22 | Substituted gamma lactams as therapeutic agents |
| EP09734653A EP2291368B1 (en) | 2008-04-24 | 2009-04-22 | Substituted gamma lactams as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2291368T3 true PL2291368T3 (pl) | 2013-05-31 |
Family
ID=40852537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09734653T PL2291368T3 (pl) | 2008-04-24 | 2009-04-22 | Podstawione gama laktamy jako środki terapeutyczne |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7820661B2 (pl) |
| EP (1) | EP2291368B1 (pl) |
| JP (1) | JP5524181B2 (pl) |
| KR (1) | KR20110008263A (pl) |
| CN (1) | CN102076681A (pl) |
| AU (1) | AU2009239372B2 (pl) |
| BR (1) | BRPI0911347A2 (pl) |
| CA (1) | CA2722529A1 (pl) |
| CO (1) | CO6321273A2 (pl) |
| DK (1) | DK2291368T3 (pl) |
| ES (1) | ES2399314T3 (pl) |
| IL (1) | IL208899A0 (pl) |
| MX (1) | MX2010011636A (pl) |
| MY (1) | MY150518A (pl) |
| PL (1) | PL2291368T3 (pl) |
| RU (1) | RU2543379C2 (pl) |
| UA (1) | UA103616C2 (pl) |
| WO (1) | WO2009132088A1 (pl) |
| ZA (1) | ZA201007553B (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| PL1654002T5 (pl) | 2003-08-07 | 2014-06-30 | Allergan Inc | Kompozycje do dostarczania środków terapeutycznych do oczu |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8377984B2 (en) * | 2008-01-29 | 2013-02-19 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
| US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| EP2288385A2 (en) * | 2008-04-16 | 2011-03-02 | Allergan, Inc. | Combination therapy for glaucoma |
| BRPI0911406A2 (pt) * | 2008-04-24 | 2015-10-06 | Allergan Inc | gama lactames substituídos como agentes terapêuticos |
| EP2285775B1 (en) * | 2008-05-20 | 2017-03-22 | Allergan, Inc. | Lactams and their use in the treatment of inter alia ocular hypertension or baldness |
| US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
| SG10201805840WA (en) * | 2009-11-09 | 2018-08-30 | Allergan Inc | Compositions and methods for stimulating hair growth |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| AU2013306012B2 (en) * | 2012-08-21 | 2018-02-08 | Allergan, Inc. | Process for the synthesis of substituted gamma lactams |
| US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
| ES2757798T3 (es) * | 2014-10-02 | 2020-04-30 | Allergan Inc | Profármacos de éster de gamma-lactamas y su uso |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US395798A (en) * | 1889-01-08 | reason | ||
| US4007210A (en) | 1973-04-27 | 1977-02-08 | American Cyanamid Company | Novel 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanates |
| US3985798A (en) | 1975-01-27 | 1976-10-12 | American Cyanamid Company | 11α-HOMO-PROSTANOIC ACIDS AND ESTERS |
| US4060540A (en) | 1975-09-18 | 1977-11-29 | American Cyanamid Company | Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3850676T2 (de) | 1987-09-18 | 1994-11-03 | R Tech Ueno Ltd | Hypotensive okulare Mittel. |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US4994274A (en) | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| CA2021316C (en) | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5288754A (en) | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
| US5721273A (en) | 1993-12-15 | 1998-02-24 | Alcon Laboratories, Inc. | Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension |
| US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US6034413A (en) * | 1997-02-27 | 2000-03-07 | Texas Instruments Incorporated | High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| PL368046A1 (pl) * | 2001-07-16 | 2005-03-21 | F.Hoffmann-La Roche Ag | Analogi prostaglandyny jako agoniści receptora EP4 |
| ATE305463T1 (de) | 2001-11-05 | 2005-10-15 | Allergan Inc | Omega-zykloalkyl 17-heteroaryl prostaglandin-e2- analoga als ep2-rezeptoragonisten |
| RU2306309C2 (ru) * | 2002-03-05 | 2007-09-20 | Оно Фармасьютикал Ко., Лтд. | Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| JP4754820B2 (ja) | 2002-06-10 | 2011-08-24 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγラクタムおよびその使用 |
| AU2003275838A1 (en) | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
| US7015243B2 (en) | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| US7091231B2 (en) | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| WO2006069276A2 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | TRICYCLIC ō-OPIOID MODULATORS |
| NZ560691A (en) | 2005-03-10 | 2011-03-31 | Allergan Inc | Substituted gamma lactams as therapeutic agents |
| US8039507B2 (en) | 2005-06-29 | 2011-10-18 | Allergan, Inc. | Therapeutic substituted gamma lactams |
| US7592364B2 (en) | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| AU2007226957B2 (en) * | 2006-03-20 | 2013-08-15 | Allergan, Inc. | Substituted gamma lactams as prostaglandin EP2 agonists |
| AU2007286177B2 (en) | 2006-08-11 | 2012-06-14 | Allergan, Inc. | Therapeutic lactams |
| US7507817B2 (en) | 2006-11-17 | 2009-03-24 | Allergan, Inc. | Prostaglandin prodrugs |
| AU2008210559B2 (en) * | 2007-01-31 | 2014-03-06 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7589213B2 (en) | 2007-04-27 | 2009-09-15 | Old David W | Therapeutic substituted lactams |
| BRPI0911406A2 (pt) * | 2008-04-24 | 2015-10-06 | Allergan Inc | gama lactames substituídos como agentes terapêuticos |
-
2009
- 2009-04-22 BR BRPI0911347A patent/BRPI0911347A2/pt not_active IP Right Cessation
- 2009-04-22 MX MX2010011636A patent/MX2010011636A/es active IP Right Grant
- 2009-04-22 US US12/427,968 patent/US7820661B2/en active Active
- 2009-04-22 EP EP09734653A patent/EP2291368B1/en active Active
- 2009-04-22 CA CA2722529A patent/CA2722529A1/en not_active Abandoned
- 2009-04-22 PL PL09734653T patent/PL2291368T3/pl unknown
- 2009-04-22 CN CN2009801242132A patent/CN102076681A/zh active Pending
- 2009-04-22 MY MYPI20105007 patent/MY150518A/en unknown
- 2009-04-22 UA UAA201013802A patent/UA103616C2/ru unknown
- 2009-04-22 DK DK09734653.0T patent/DK2291368T3/da active
- 2009-04-22 RU RU2010144637/04A patent/RU2543379C2/ru active
- 2009-04-22 JP JP2011506415A patent/JP5524181B2/ja not_active Expired - Fee Related
- 2009-04-22 KR KR1020107026219A patent/KR20110008263A/ko not_active Application Discontinuation
- 2009-04-22 AU AU2009239372A patent/AU2009239372B2/en active Active
- 2009-04-22 ES ES09734653T patent/ES2399314T3/es active Active
- 2009-04-22 WO PCT/US2009/041389 patent/WO2009132088A1/en active Application Filing
-
2010
- 2010-10-22 ZA ZA2010/07553A patent/ZA201007553B/en unknown
- 2010-10-24 IL IL208899A patent/IL208899A0/en unknown
- 2010-11-22 CO CO10145796A patent/CO6321273A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2543379C2 (ru) | 2015-02-27 |
| RU2010144637A (ru) | 2012-05-27 |
| MX2010011636A (es) | 2010-11-25 |
| CA2722529A1 (en) | 2009-10-29 |
| IL208899A0 (en) | 2011-01-31 |
| AU2009239372A1 (en) | 2009-10-29 |
| MY150518A (en) | 2014-01-30 |
| UA103616C2 (ru) | 2013-11-11 |
| EP2291368B1 (en) | 2012-12-19 |
| WO2009132088A1 (en) | 2009-10-29 |
| JP5524181B2 (ja) | 2014-06-18 |
| US7820661B2 (en) | 2010-10-26 |
| JP2011518833A (ja) | 2011-06-30 |
| BRPI0911347A2 (pt) | 2018-03-20 |
| CN102076681A (zh) | 2011-05-25 |
| EP2291368A1 (en) | 2011-03-09 |
| DK2291368T3 (da) | 2013-03-18 |
| AU2009239372B2 (en) | 2013-09-19 |
| ZA201007553B (en) | 2011-08-31 |
| KR20110008263A (ko) | 2011-01-26 |
| ES2399314T3 (es) | 2013-03-27 |
| CO6321273A2 (es) | 2011-09-20 |
| US20090270392A1 (en) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208899A0 (en) | Substituted gamma lactams as therapeutic agents | |
| HK1223851A1 (zh) | 作為治療劑的取代的γ內酰胺 | |
| GB0811304D0 (en) | Therapeutic agents | |
| EP2320907A4 (en) | THERAPEUTIC COMPOUNDS | |
| HK1253355A1 (zh) | 含有馬西替坦的治療組合物 | |
| GB0811643D0 (en) | New therapeutic agents | |
| EP2268285A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0819593D0 (en) | Therapeutic agents | |
| GB0806794D0 (en) | Therapeutic compounds | |
| GB0821693D0 (en) | Therapeutic agents | |
| GB0813740D0 (en) | Therapeutic compounds | |
| IL205278A0 (en) | Therapeutic substituted lactams | |
| GB0812309D0 (en) | Therapeutic agents | |
| GB0805818D0 (en) | Therapeutic agents | |
| GB0804755D0 (en) | Therapeutic compounds | |
| GB0801080D0 (en) | Therapeutic agents | |
| GB0801081D0 (en) | Therapeutic agents | |
| BRPI0906631A2 (pt) | Gama lactamos substituídos agentes terapêuticos | |
| EP2454276A4 (en) | THERAPEUTIC AGENTS | |
| GB0811715D0 (en) | Therapeutic agents | |
| GB0801082D0 (en) | Therapeutic agents | |
| GB0812563D0 (en) | Therapeutic agents | |
| GB0815177D0 (en) | Therapeutic agents | |
| GB0820275D0 (en) | Therapeutic agents | |
| GB0812558D0 (en) | Therapeutic agents |